Acute nonlymphocytic leukemia: Onset after treatment for Hodgkin's disease

Annals of Hematology

Volumn 74, Issue 3, 1997, Pages 103-110

  Enrici, R Maurizi ^a   Anselmo, A P ^b   Osti, M F ^b   Santoro, M ^b   Sbarbati, S ^b   Tombolini, V ^b   Mandelli, F ^b   D'Arcangelo, E ^b   Biagini, C ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute nonlymphocytic leukemia; Chemotherapy; Hodgkin's disease; Radiotherapy; Risk factors

Indexed keywords

CHLORMETHINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CULTURE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK FACTOR; SPLENECTOMY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HODGKIN DISEASE; HUMANS; KARYOTYPING; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; SPLEEN; SPLENECTOMY;

EID: 1842413621     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050266     Document Type: Article

References (54)

1. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaloy S, Host H (1993) Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 11:255-261
2. Amadori S, Papa G, Anselmo AP, Fidani P, Mandelli F (1983) Acute promyelocytic leukemia following ABVD (doxorubicin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease. Cancer Treat Rep 67:603-604
3. Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G (1990) Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8:1148-1154
4. Baccarani M, Bosi A, Papa G, writing committee for the Gigi Ghirotti task force for malignant lymphoma (1980) Second malignancy in patients treated for Hodgkin's disease. Cancer 46:1735-1740
5. Benedetti J, Yenu K, Young L (1983) Life tables and survival functions. In: Dixon WJ (eds) BMDP statistical software. University of California Press, Berkeley, pp 557-575
6. Bennett JM, Moloney WC, Greene MH, Boice JD jr (1987) Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents. Hematol Pathol 1:99-107
7. Blayney DW, Longo DL, Young RC Greene MH, Hubbard SM, Postal MG, Duffey PL, De Vita VT (1987) Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 19:7170-7176
8. Brusamolino E, Papa G, Valagussa P, Mandelli F, Bernasconi C, Marmont A, Bonadonna G, Tura S, Bosi A, Mango G, Mazza P, Rossi E, Leoni F, D'Onofrio G, D'Arcangelo E (1987) Treatment-related leukemia in Hodgkin's disease: a multi-institution study of 75 cases. Haematol Oncol 5:83-98
9. Cimino G, Papa G, Tura S, Rossi Ferrini PL, Bosi A, Amadori S, Lo Coco F, D'Arcangelo E, Giannarelli D, Mandelli F (1991) Second primary cancer following Hodgkin's disease: updated results of an italian multicentric study. J Clin Oncol 9:432-437
10. Coleman CN, Kaplan HS, Cox R, Varghese A, Butterfield P, Rosenberg SA (1982) Leukemias, non-Hodgkin's lymphomas and solid tumors in patients treated for Hodgkin's disease. Cancer Survey 1:733-744
11. Coleman CN, McDougall IR, Daley MO, Ager P, Bush S, Kaplan H (1982) Functional hyposplenia after splenic irradiation for Hodgkin's disease. Ann Intern Med 96:44-47
12. Daley MO, Coleman CN, Kaplan HS (1980) Radiation-induced splenic atrophy in patients with Hodgkin's disease and non-Hodgkin's lymphomas. N Engl J Med 302:215-217
13. Daley MO, Coleman CN, Fajardo LF (1981) Splenic injury caused by therapeutic irradiation. Am J Surg Pathol 5, 325- 331
14. Devereux S, Selassie G, Vaughan-Hudson G, Vaughan-Hudson B, Linch DC (1990) Leukemia complicating treatment for Hodgkin's disease: the experience of the BNLI. BMJ 301:1077-1080
15. Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M (1994) Second primary cancer in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen. Blood 84:1209-1215
16. Greene MH, Boice JD jr, Greer BE, Blessing JA, Dembo AJ (1982) Acute non-lymphocytic leukaemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med 307:1416-1421
17. Henry-Amar M (1992) Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 3:117-128 [Suppl 4]
18. Hofmann WK, Ottmann OG, Ganser A, Hoelzer D (1996) Myelodysplastic syndromes: clinical features. Semin Hematol 33:177-185
19. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA (1989) Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 72:40-44
20. Hoppe RT (1992) Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease. Leukemia 6:155-157 [Suppl 4 P]
21. Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry- Amar M, Fiorentino MV, Bell J, Pederson D, Band P, Assouline D, Koch M, Choi W, Prior P, Blair V, Langmark F, Kim VP, Neal F, Peters D, Pfeiffer R, Karjalainen S, Cuzick J, Sutcliffe SB, Somers R, Pellae-Cosset B, Pappagallo GL, Fraser P, Storm H, Stovall M (1990) Leukemia following Hodgkin's disease. N Engl J Med 322:7-13
22. Kantarijian HM, Keating MJ, Walzers RS, Smith TL, Cork A, McCredie KB, Freireich EJ (1986) Therapy-related leukemia and myelodysplastic syndromes: clinical, cytogenetic, and prognostic features. J Clin Oncol 4:1748-1757
23. Kantarijian HM, Estey EH, Keating MJ (1993) Treatment of therapy-related leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am 7:81-107
24. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
25. Levine EG, Blomfield CD (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47-84
26. Maurizi Enrici R, Anselmo AP, Osti MF, Sbarbati S, Tombolini V, Biagini C (1993) Methods of assessment of delayed damage in patients treated for Hodgkin's disease. Minutes of the XX AIRB Congress, Sept. 29-30, pp 152-170
27. Mellemkjoer L, Olsen JH, Linet MS, Linet AMS, Gridley G, McLaughlin JK (1995) Cancer risk after splenectomy. Cancer 75:577-583
28. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ (1994) Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83:3780-3786
29. Papa G, Mauro FR, Anselmo AP, Cimino G, Alimena G, Amadori S, D'Arcangelo E, Giannarelli D, Bosi A, Bellesi G, Fiacchini M, Mazza P, Babini L, Emiliani E, Maurizi Enrici R, Biagini C (1984) Acute leukemia in patients treated for Hodgkin's disease. Br J Haematol 58:43-52
30. Park DJ, Koeffler HP (1996) Therapy-related myelodysplastic syndromes. Semin Hematol 33:256-273
31. Parmentier C, Morardet N, Tubiana M (1983) Late effects on human bone marrow after extended field radiotherapy. Int J Radiat Oncol Biol Phys 9:1303-1311
32. Pearson HA, Johnston D, Smith KA, Touloukian RJ (1978) The born-again spleen: return of splenic function after splenectomy for trauma. N Engl J Med 298:1389-1392
33. Pedersen-Bjergaard J, Rowley JD (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may developed in different ways and may contribute differently to malignant transformation. Blood 83:2780- 2786
34. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K (1990) Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1091
35. Pedersen-Bjergaard J, Pederson M, Roulston D, Philip P (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542- 3552
36. Rodriguez MA, Fuller LM, Zimmermann SO, Allen PK, Brown BW, Munsell MF, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F Jr, Cabanillas FF (1993) Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 4:125-131
37. Rubin CM, Larson RA, Anastasi J, Winter JN, Thangavelu M, Vardiman JW, Rowley JD, Le Beau MM (1990) t (3; 21) (q26; q22), a recurring chromosomal abnormality in therapy- related myelodysplastic syndrome and acute myeloid leukemia. Blood 76:2594-2598
38. Sont JK, Van Stiphout WAH, Noordijk EM, Molenaar J, Zwetsloot-Schonk JHM, Willemze R, Vandenbrouke JP (1992) Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Hematol 65:213-218
39. Smith MA, Me Caffrey RP, Karp JE (1996) The secondary leukemias: challenges and research directions. J Natl Cancer Inst 88:407-418
40. Swerdlow AJ, Douglas AJ, Vaughan-Hudson G, Vaughan- Hudson B, Bennet MH, McLennan KA (1992) Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma investigation. BMJ 304:1137-1143
41. Tura S, Canellos G, Goldstone A, Longo D, McMillan A, Urba W, Zinzani PL (1991) Hodgkin's disease: controversies and challenges for the future. Haematologica (Pavia) 76:263- 279
42. Tura S, Fiacchini M, Zinzani PL, Brusamolino E, Gobbi PG (1993) Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol 11:925- 930
43. Urba WJ, Longo DL (1992) Hodgkin's disease. N Engl J Med 326:678-687
44. Valagussa P (1963) Second neoplasm following treatment of Hodgkin's disease. Curr Opin Oncol 5:805-811
45. Valagussa P, Santoro A, Fossati-Bellani F, Franchi F, Banfi A, Bonadonna G (1982) Absence of treatment-induced second neoplasm after ABVD in Hodgkin's disease. Blood 59:488-494
46. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G (1986) Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837
47. Van der Velden JW, Van Putten WLJ, Guinee VF, Pfeiffer R, Van Leeuwen FE, Van der Linden EAM, Vardomskaya I, Lanf W, Durand M, Lagarde C, Hagemeister FB, Hagenbeek A, Eghbali H (1988) Subsequent development of acute non lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer 42:252-255
48. Van Leeuwen FE, Somers R, Hart AM (1987) Splenectomy in Hodgkin's disease and second leukemia. Lancet 2:210- 211
49. Van Leeuwen FE, Somers R, Taal BG, Van Heerde P, Coster B, Dozeman T, Huisman SJ, Hart AAM (1989) Increased risk of lung cancer, non-Hodgkin lymphoma and leukemia following Hodgkin's disease. J Clin Oncol 7:1046-1058
50. Van Leeuwen FE, Chorus AMJ, Van den Belt-Dusebout AW, Hagenbeek A, Noyon R, Van Kerkhoff EHM, Pinedo HM, Somers R (1994) Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073
51. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, Van den Belt-Dusebout AW, van Kerkhoff EHM, van Heerde P, Somers R (1994) Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 12:312-325
52. Yahalom J, Voss R, Leizerowitt R, Fuks ZVI, Polliack A (1983) Secondary treatment on Hodgkin's disease: ultrastructural and cytogenetic data in two cases with a review of the literature. Am J Clin Pathol 80:231-236
53. Young RC, Bookman MA, Longo DL (1990) Late complications of Hodgkin's disease management. Natl Cancer Inst Monogr 10:55-60
54. Zinzani PL, Fiacchini M, Mazza P, Gherlinzoni F, Bocchia M, Tura S (1991) Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia. Haematologica (Pavia) 765:305-310